Thus, PFKFB4 has good potential to be a therapeutic target to overcome drug resistance to palbociclib in ER+ BC and more efforts are needed to develop safe and efficient PFKFB4‐targeted drug and undertake clinical translation in the future. Here, PFKFB4 is linked to breast cancer.